Accenture plc’s ACN Accenture Interactive announced yesterday that it has agreed to acquire French data and digital oriented consulting firm group — Sutter Mills. Financial terms have been kept under wraps.
Sutter Mills is a provider of consulting and implementation services that help clients improve customer insights and enhance efficacy of marketing strategies. It would be Accenture’s fifth acquisition in France in four years, following acquisitions of Cirruseo in 2019, Arismore and Altima in 2017, and OCTO Technology in 2016.
Sutter Mills’ addition will help Accenture Interactive increase its data-driven marketing strategy, adtech and martech capabilities.
Olivier Girard, country managing director of Accenture in France and Benelux said, “By helping companies better exploit data to create hyper-personalized interactions that influence consumers’ buying decisions while enabling them to measure the return on their marketing investments, we can give chief marketing officers the tools needed to demonstrate their contribution to their companies’ growth.”
We observe that Accenture shares have gained 32.3% year to date, outperforming the 30% rally of the industry it belongs to.
Accenture has been strengthening its digital marketing capabilities through frequent acquisitions. Considering the growing need for digital marketing, we expect the company’s investment in digital and marketing capabilities to boost long-term growth. This will also help it to better compete with other digital marketing service providers such as International Business Machines IBM, Dell Technologies DELL and Deloitte.
Zacks Rank & Stocks to Consider
Accenture currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the broader Zacks Business Services sector is CoreLogic CLGX, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings (three to five years) growth rate for CoreLogic is estimated at 11%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
International Business Machines Corporation (IBM) : Free Stock Analysis Report
Dell Technologies Inc. (DELL) : Free Stock Analysis Report
CoreLogic, Inc. (CLGX) : Free Stock Analysis Report
Accenture PLC (ACN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research